Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ConocoPhillips (COP) vs Summit Therapeutics Inc (SMMT) Price & Performance

ConocoPhillipsTrade
Summit Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

ConocoPhillips vs Summit Therapeutics Inc — how do they compare? ConocoPhillips trades at $125.19 (market cap $151.27B), while Summit Therapeutics Inc trades at $15.56 (market cap $12.06B). The key difference: ConocoPhillips is far larger — about 12.5× Summit Therapeutics Inc's market cap, and ConocoPhillips pays a 2.67% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.

COPSMMT
Market Cap
$151.27B$12.06B
Sector
EnergyHealth
52-Week High
$133.80$26.98
52-Week Low
$85.66$12.55
Enterprise Value
$166.87B$11.39B
Dividend Yield
2.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ConocoPhillips

ConocoPhillips (COP) trades at $123.03, up 4.61% on the day, with a bullish technical signal from moving averages and strong Q2 2026 earnings beats. The company reported EPS of $3.24 versus $2.90 expected, driven by higher oil prices and Permian Basin output. Recent CEO transition to Andy O'Brien signals continuity, with a consensus analyst price target of $150.00 indicating 22% upside potential.

Outlook remains positive due to robust free cash flow growth and favorable commodity trends, though risks include oil price volatility and execution of the Alaska project. The stock offers value with a P/E of 16.66 and a net income margin of 14.65%, supported by a 74.51% buy rating from analysts.

Summit Therapeutics Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ConocoPhillips

ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.

Read more on COP

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT